Purple loosestrife

Purple Loosestrife (Lythrum salicaria L.): A Comprehensive Reference

1. Identity and Botanical Description

1.1 Nomenclature and Taxonomy

Purple loosestrife (Lythrum salicaria L.) is a herbaceous perennial plant belonging to the Lythraceae family. The generic name Lythrum comes from the Greek word luthron, meaning "blood," possibly referring to the color of the flowers or to one of its herbal uses as an astringent. Its Latin species epithet salicaria refers to the shape of the leaves, which resemble those of a willow (Salix).

Its English common names include "blooming sally," "purple willow-herb," "rainbow weed," and "purple loosestrife." In Turkish traditional medicine it is known as Tibbi hevhulma, and in Persian it is known by the names "Turbinkwash," "Yerpoose," and "Surmankhal." The drug material derived from the plant's aerial parts is officially designated Lythri herba in pharmacopoeial texts.

The genus Lythrum comprises approximately 30 species of herbaceous annual or perennial flowering plants. Synonyms for L. salicaria L. according to the Plant List include Lythrum argyi H. Lév., Lythrum intermedium Ledeb. ex Colla, and Lythrum tomentosum Mill.

1.2 Botanical Description and Native Range

According to Flora Europaea, L. salicaria is an erect perennial herb, 0.5–1.5 m high, subglabrous to densely gray pubescent, with a stem bearing four or more raised lines and being sparingly branched. The plant is almost cosmopolitan in distribution, growing in Europe, Asia, and North Africa; it prefers damp, watery places and can be found on the banks of streams, ponds, and lakes, as well as in damp ditches, meadows, and fens.

L. salicaria is originally Eurasian, but during the 19th century it was spread via the ballast of European ships not only throughout Europe but also into North and South America, as well as Australia. It was reportedly introduced to the USA in the early 1800s via ships' ballast and livestock. Though popularly cultivated for its ornamental and pharmacological values, L. salicaria is today a major invasive plant in North American wetlands and is considered one of the 100 worst invasive alien species in the world by the International Union for the Conservation of Nature (Invasive Species Specialist Group).

1.3 Plant Parts Used and Common Preparations

Lythri herba — the dried flowering tops — is officialized in the European Pharmacopoeia, 10th edition. Purple loosestrife contains tannins, flavonoids and phenolcarboxylic acids, as well as anthocyanidins (colorants in the flower), and the quality of purple loosestrife (Lythri herba) is specified in the European Pharmacopoeia. The Lythri herba monograph was taken from the French Pharmacopoeia for introduction into the European Pharmacopoeia.

Common preparations reported in traditional and folk medicine include aqueous infusions (teas), decoctions, fluid extracts, and topical ointments. The drug is used in folk medicine, mainly in France, to treat diarrhea, as are other "tannin drugs" such as lady's mantle herb, agrimony, and goose cinquefoil. For tea preparation, a cup is drunk several times a day between meals; approximately 150 mL of boiling water is poured over 2 to 5 g of finely cut purple loosestrife and strained after 10 minutes.

In research settings, extracts have been prepared using a range of solvents — including petroleum ether, ethyl acetate, methanol, 50% aqueous methanol, ethanol (at 70% and 96% concentrations), and water — with 70% ethanol and aqueous extracts yielding the highest total phenolic content in comparative studies.

2. Historical and Traditional Use

2.1 Ancient and Classical Medicine

Purple loosestrife has been known as a medicinal plant from ancient Greek and Roman times and has been an important drug for centuries. A review of historical sources from ancient times through the 20th century has revealed an outstanding position of L. salicaria in traditional medicine, with the main applications being gastrointestinal tract ailments (mainly dysentery and diarrhea) as well as different skin and mucosa affections.

2.2 European Traditional Medicine

The herb of purple loosestrife was used in Europe since ancient times through the early 20th century in the therapy of diarrhea and dysentery in both human and veterinary medicine. Purple loosestrife has been traditionally used in Europe for therapeutic purposes, to treat diseases with an inflammatory background, such as hemorrhoids, dysentery, chronic intestinal catarrh, and eczema. Since it is considered a strong astringent and hemostatic agent, this plant is used in cases of diarrhea and hemorrhages.

Its effectiveness may be validated from historical sources reporting its use during dysentery epidemics in the 18th and 19th centuries and in military hospitals during World War I. Due to the introduction of antibiotics and chemotherapeutics, it subsequently lost its important position in the therapy of diarrhea.

It is also popularly used as an astringent for inflammation of the gastric mucosa. In Turkish folk medicine, L. salicaria (known as "Tibbi hevhulma") is used in the form of a decoction or fluid extract against diarrhea, chronic intestinal catarrh, hemorrhoids, and eczema, and externally to treat varicose veins, bleeding of the gums, hemorrhoids, and eczema.

2.3 Iranian and Near Eastern Traditional Use

In the folk medicine of northwestern Iran, the aerial parts of the plant have been traditionally employed for the treatment of diarrhoea, dysentery, inflammation of the intestine, haematuria, leucorrhoea, epistaxis, and dysmenorrhoea; externally, the plant was used for cleaning impetigo, eczema, lupus, and inflammation of the female genito-urinary system.

2.4 Veterinary Traditional Use

The herb was used both in traditional and official medical treatment of diarrhea in humans and farm animals. Herb of purple loosestrife was used in Europe since ancient times through the early 20th century in the therapy of diarrhea and dysentery in human and veterinary medicine.

3. Phytochemistry: Key Constituents and Active Compounds

3.1 Overview of Chemical Composition

Lythrum salicaria contains a wide range of chemical constituents, including alkaloids, tannins, anthocyanins, glycosides (salicairine), triterpenes, sterols, steroids, organic acids, phenolic acids, and flavonoids. L. salicaria is a rich source of polyphenols including ellagitannins, tannin-related compounds, flavonoids, flavan-3-ols, phenolic acids, and anthocyanins; apart from phenolics, the presence of nonpolar compounds belonging to different chemical groups such as steroids, triterpenes, phthalates, and coumarins has been confirmed in extracts.

3.2 Ellagitannins (Primary Pharmacologically Active Constituents)

Lythri herba is known as a tannin-rich plant material, but the first study dealing with the chemical structures of purple loosestrife ellagitannins dates from the mid-1990s. The main specialized metabolites of Lythrum salicaria herb belong to two groups: C-glycosylic ellagitannins (CGEs) — specifically vescalagin, castalagin, and the species-characteristic dimeric forms salicarinins A, B, and C — and C-glycosylic flavonoids (vitexin, orientin, and isoorientin).

The main compounds on which pharmacopoeial standardization is based (according to the European Pharmacopoeia) are tannins; C-glucosidic monomeric ellagitannins (vescalagin and castalagin) and dimeric ellagitannins (salicarinins A, B, and C) have been shown to be the dominant compounds in aqueous extracts.

Quantitative evaluation of total polyphenols, tannins, and anthocyanins content in Lythri herba has revealed values of 16.39% in polyphenols, 10.53% tannins, and 0.3598% anthocyanosides, results comparable to findings in the broader literature.

3.3 C-Glycosidic Flavonoids

L. salicaria contains a notable amount of flavonoids, mainly C-glycosides of the flavones apigenin (vitexin and isovitexin) and luteolin (orientin and isoorientin). Extracts of L. salicaria L. have been reported to contain high amounts of phenolic acids including caffeic, chlorogenic, isochlorogenic, ellagic, and gallic acids, as well as flavonoids such as apigenin, catechin, quercetin-3-D-galactoside, luteolin, orientin, isoorientin, rutin, vitexin, and isovitexin.

3.4 Polysaccharide–Polyphenolic Conjugates

A high-molecular-mass polysaccharide–polyphenolic conjugate has been isolated from the flowering parts of Lythrum salicaria by hot alkaline extraction; chemical analysis revealed 74% carbohydrates and 17% phenolics. Compositional analysis of the carbohydrate portion showed a high galacturonic acid content (49%), along with rhamnose (25%), galactose (13%), and arabinose (9%), indicating a rhamnogalacturonan associated with arabinogalactan in the Lythrum conjugate.

3.5 Other Phytochemical Classes

Apart from phenolics, the presence of compounds belonging to diverse chemical classes — including steroids, triterpenes, phthalates, and coumarins — has been confirmed in extracts of L. salicaria. The plant also contains alkaloids (including quinolizidine-type structures) and anthocyanins that contribute to the characteristic blue-purple coloration of the flowers.

4. Mechanisms of Action

4.1 Astringency and Antidiarrheal Mechanism

The pharmacological activity of L. salicaria is mostly due to its phenolic compounds, mainly tannins. Tannins exert their antidiarrheal and astringent effects primarily by precipitating proteins on mucosal surfaces and reducing intestinal secretion and permeability. Lythri herba (LSH) was found not only to inhibit enteropathogenic Escherichia coli (EPEC) growth in a concentration-dependent manner but also its adhesion to IPEC-J2 intestinal epithelial cell monolayers. Inhibitory activity toward EPEC growth was additionally confirmed ex vivo in distal colon samples of post-weaning piglets.

4.2 Antioxidant Mechanisms

Multiple in vitro studies have demonstrated free-radical scavenging capacity attributable to the plant's high polyphenol content. Extracts have demonstrated antioxidant activity by scavenging DPPH and ABTS free radicals; among individual bioactive compounds, gallic acid showed the strongest activity against DPPH free radicals, followed by ellagic acid and caffeic acid. The antioxidant effect of ethanolic extract of Lythrum salicaria was studied using superoxide anion radical scavenging activity and lipid peroxidation tests; the ethanol extract showed concentration-dependent superoxide anion radical scavenging activity and an inhibitory effect on lipid peroxidation.

4.3 Anti-inflammatory and Antinociceptive Mechanisms

Antioxidant, anti-inflammatory, and anti-nociceptive activities of extracts have been investigated using in vitro and in vivo methods, including free radical scavenging activity (DPPH assay), iron(III) reductive activity, and capacity for inhibition of linoleic acid peroxidation and MDA formation, as well as an anti-nociceptive activity test (p-benzoquinone-induced abdominal constriction test).

4.4 Antimicrobial Mechanisms

The whole plant has shown antibiotic properties, especially against bacteria Staphylococcus aureus, Proteus mirabilis, Micrococcus luteus, and the yeast Candida albicans. The antimicrobial activity is primarily attributed to tannins and other polyphenols, which disrupt microbial cell membranes and inhibit protein synthesis in pathogens.

4.5 Hemostatic and Coagulant Mechanisms

Some studies have shown that glycoconjugates from flowering parts of L. salicaria manifested pro-coagulant activity. Additionally, polysaccharide–polyphenol conjugates isolated from this plant were reported to possess antitussive and bronchodilatory properties, as well as controversial anticoagulant and pro-coagulant effects.

4.6 Antitussive and Bronchodilatory Mechanisms

Antitussive activity tests performed on the Lythrum polysaccharide–polyphenolic conjugate at three doses (25, 50, and 75 mg/kg of animal body weight) showed the reduction of cough efforts even 5 hours after administration, though the antitussive effects were lower than those of codeine. Tests evaluating the influence of different doses on airway smooth muscle reactivity revealed a more significant bronchodilatory effect of the Lythrum conjugate compared with salbutamol, a commercial bronchodilator used in clinical practice. Measurements of specific airway resistance pointed to dose-dependent bronchodilatory activity and a possible contribution of bronchodilation to the antitussive effect.

5. Scientific Evidence by Area of Application

5.1 Gastrointestinal Disorders (Diarrhea, Dysentery)

Evidence level: Preclinical (in vitro, ex vivo, animal); no controlled human clinical trials identified.

The antidiarrheal effect of a liquid extract from the fresh plant has been confirmed. The contemporary pharmacological research is, however, still insufficient to support the plant's thoroughly described traditional uses, and the necessity of complex studies regarding modes of action that would directly refer to L. salicaria's main traditional applications — gastrointestinal tract ailments — is strongly underlined.

A 2021 study published in the Journal of Natural Products (PMC7771025) directly investigated the plant's primary mode of action for diarrhea. Taking into consideration the historical use of LSH in the treatment of diarrhea in humans and farm animals, the study examined in vitro the influence of LSH and its C-glycosylic ellagitannins on processes associated with maintaining intestinal epithelium integrity and EPEC growth and adhesion. LSH not only inhibited EPEC growth in a concentration-dependent manner but also its adhesion to IPEC-J2 intestinal epithelial cell monolayers; inhibitory activity toward EPEC growth was additionally confirmed ex vivo in distal colon samples of post-weaning piglets.

A separate study (PubMed, PMID 32673710) assessed the interaction of LSH with gut microbiota in healthy post-weaning piglets. Lythrum salicaria herb fulfilled the criteria of a potential candidate for an antidiarrheal agent, which could be applied as therapy or prevention of post-weaning diarrhea in piglets; it not only modulated gut microbiota composition without causing dysbiosis and impairing metabolic activity, but was also a source of postbiotic metabolites — namely urolithins — whose anti-inflammatory properties can be beneficial for gut health during the weaning period. Urolithins are microbial metabolites produced from ellagitannin precursors.

These results are entirely preclinical. No randomized or controlled human clinical trials investigating purple loosestrife for any gastrointestinal indication have been identified in the peer-reviewed literature.

5.2 Antioxidant Activity

Evidence level: In vitro; animal model support; no human clinical trials.

L. salicaria ethanol extracts showed the highest DPPH free-radical scavenging (378.60 µM TE/g) and reducing power (684.06 µM TE/g), while its aqueous extract exhibited the highest ABTS activity (3621.93 µM TE/g) among a panel of six medicinal plants from Serbian traditional medicine tested in a 2026 study.

In a study from Iran (PMC3751246), results suggested that L. salicaria has high antioxidant activity comparable to the positive standard vitamin E, which was attributed to the high content of phenolic compounds in the extract. The aqueous extract of Lythri herba showed an increased antioxidant activity (DPPH inhibition) of 94.39% at the concentration of 2.5 mg/mL, with IC50 registered at 0.2166 mg/mL.

Lythrum salicaria methanol extracts showed promising antioxidant potential and extracts demonstrated DNA-protective effects against hydroxyl and peroxyl radicals. These findings are uniformly in vitro, and no human studies have evaluated the in vivo antioxidant effects of the herb.

5.3 Antimicrobial Activity

Evidence level: In vitro; no human clinical trials.

Ethanolic extracts of Lythrum salicaria L. have shown antimicrobial activity against Gram-negative and Gram-positive bacteria such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, as well as against the fungus Candida albicans. In a 2026 comparative study, antimicrobial assays revealed higher sensitivity of Gram-positive bacteria, particularly Listeria monocytogenes and Staphylococcus aureus, with L. salicaria extracts showing among the strongest effects.

L. salicaria extracts contained a significant amount of total phenolic compounds and several phenolic compounds including C-glycoside flavones, orientin, isoorientin, and vitexin; the extracts demonstrated high antioxidant potential in different in vitro methods, moderate antimicrobial properties, and low cytotoxicity on studied normal and cancer cell lines.

A study from Iran also subjected the aqueous methanol (80%) extract to anti-Helicobacter pylori testing (using the disc diffusion method), with the conclusion that the plant exhibited low anti-H. pylori effects. All antimicrobial evidence is exclusively in vitro, with no human studies conducted.

5.4 Anti-inflammatory and Antinociceptive Activity

Evidence level: In vitro and animal model; no human clinical trials.

The aerial part of L. salicaria was demonstrated to possess pharmacological activities including antioxidant, anti-inflammatory, and antinociceptive effects in studies published as recently as 2007 from Turkey. These studies, published in Journal of Ethnopharmacology (PubMed PMID 17125946), investigated both in vitro and in vivo methods. All evidence for anti-inflammatory action remains at the preclinical level.

5.5 Antidiabetic / Hypoglycemic Activity

Evidence level: Animal model and in vitro; no human clinical trials.

A 2025 study published in PMC evaluated the potential of Lythrum salicaria L. ethanol extract (LSEE) to mitigate oxidative stress, inflammation, and metabolic and hormonal imbalances in separate experimental models of streptozotocin (STZ)-induced diabetes mellitus and letrozole-induced polycystic ovary syndrome (PCOS) in rats.

An earlier study using an aqueous methanol (80%) extract of the aerial parts in a rat model of streptozotocin-induced diabetes reported that L. salicaria has low anti-diabetic effects, which the authors attributed partly to the high content of phenolic compounds in the extract. The methanol extract was found to have inhibitory activity (p < 0.05) at 100 and 200 mg/kg doses (26.9 and 30.1% inhibition, respectively) in an in vivo antidiabetic model.

The flavonoid isoorientin — one of the characteristic C-glycosidic flavones of L. salicaria — has demonstrated hypoglycemic effects in animal models across multiple plant species and is hypothesized to exert antidiabetic effects through inhibitory activity on α-glucosidase and α-amylase enzymes, based on studies in related phytochemical contexts. Overall, antidiabetic evidence for L. salicaria itself remains preliminary, with mixed results across animal models and no human data.

5.6 Wound Healing and Dermatological Applications

Evidence level: Animal model (burn wound); in vitro cell-based assays; no human clinical trials.

A study published on PubMed (PMID 27701123) assessed the wound-healing activity of L. salicaria topical ointment in second-degree burn wounds in rats. Wound contraction percentage with L. salicaria was 89.5 ± 3.7%; a well-organized epidermal layer and normal appearance in the dermis layer were more observable in the L. salicaria group; moreover, the L. salicaria ointment displayed better influence on tissue oxidative stress parameters than the comparator or negative control. The authors concluded that results clearly confirm the effectiveness of L. salicaria topical ointment as a wound-healing agent, possibly due to considerable polyphenolic content and antioxidant properties.

A 2025 study (PMC12108421) assessed cell viability and antioxidant and wound-healing potential of optimized L. salicaria herbal extracts on keratinocytes and fibroblasts; the Lythrum salicaria optimized herbal extract showed the strongest antibacterial activity among the plant species studied. These findings support the plausibility of traditional topical uses but remain preclinical.

5.7 Antitussive and Bronchodilatory Activity

Evidence level: Animal model (guinea pig); no human clinical trials.

Antitussive activity tests performed using citric acid-induced cough reflex in guinea pigs with the Lythrum polysaccharide–polyphenolic conjugate at doses of 25, 50, and 75 mg/kg showed reduction in the number of cough efforts even 5 hours after administration; however, antitussive effects were lower in comparison with codeine. Tests evaluating the influence of different doses on airway smooth muscle reactivity revealed more significant effect of the Lythrum conjugate compared with salbutamol, a commercial bronchodilator used in clinical practice. These effects are attributed to the plant's high-molecular-mass polysaccharide–polyphenolic glycoconjugate, and represent entirely preclinical findings.

5.8 Effects on Blood Coagulation

Evidence level: In vitro and animal model; conflicting findings; no human clinical trials.

Polysaccharide–polyphenol conjugates isolated from L. salicaria have been reported to possess controversial anticoagulant and pro-coagulant effects in different experimental systems. Separate studies (cited in PMC3751246 as references 49-8 through 49-12) have investigated both anticoagulant and pro-coagulant properties of different glycoconjugate fractions, with no consistent directional conclusion.

5.9 Anticholinesterase Activity and Bone Health

Pharmacological studies have also revealed that L. salicaria exerts anticholinesterase activity and enhancement of osteoblastic proliferation, based on cell and biochemical studies; however, these areas are at an early exploratory stage with no in vivo human or extensive animal data available.

5.10 Summary of Evidence Strength

Contemporary pharmacological research is still insufficient to support the plant's thoroughly described traditional uses. The entire body of human-relevant evidence for purple loosestrife in any therapeutic area remains preclinical — confined to in vitro experiments, ex vivo tissue studies, and animal models. No randomized controlled trials, prospective cohort studies, or other human clinical trials on Lythrum salicaria as a dietary supplement or medicinal preparation have been identified in the peer-reviewed literature.

6. Body Systems Associated With Purple Loosestrife

• Gastrointestinal system: Antidiarrheal, astringent, antiulcer, intestinal anti-infective, intestinal epithelium barrier support
• Integumentary system (skin and mucosae): Wound healing, eczema, hemorrhoidal tissue, anti-inflammatory on mucosae
• Cardiovascular/hematological system: Hemostatic, astringent on bleeding surfaces (gums, varicose veins), with complex and conflicting coagulation effects
• Respiratory system: Antitussive, bronchodilatory (animal model evidence only)
• Metabolic/endocrine system: Antidiabetic, antihyperglycemic (animal model evidence only)
• Immunological/oxidative stress: Antioxidant, anti-inflammatory, potential immunomodulatory effects
• Microbial/infectious: Antimicrobial against a range of Gram-positive and Gram-negative bacteria and Candida albicans

7. Dosage Forms and Reported Dosages

In folk medicine tea preparations, a cup is consumed several times a day between meals; the preparation involves pouring approximately 150 mL of boiling water over 2 to 5 g of finely cut purple loosestrife and straining after 10 minutes.

In experimental research studies, the following dosages have been reported:

• Polysaccharide–polyphenolic conjugate at doses of 25, 50, and 75 mg/kg of animal body weight in antitussive activity tests using citric acid-induced cough reflex in guinea pigs.
• Methanol extract at 100 and 200 mg/kg doses in in vivo antidiabetic tests (rat streptozotocin model), resulting in 26.9% and 30.1% inhibition of blood glucose elevation, respectively.
• Total flavonoid content of 5.8 ± 0.4 µg QE/mg extract and total phenol content of 331 ± 3.7 µg GAE/mg extract were reported for the aqueous methanol (80%) extract; the IC50 value for DPPH inhibition of the plant extract was 13.5 µg/mL.

Despite being reported in the European Pharmacopoeia as "Lythri herba," L. salicaria is not listed by the European Medicines Agency's Committee on Herbal Medicinal Products, and its preparations are not available on the market. No standardized human dosage has been formally established through regulatory review.

8. Safety Considerations

8.1 Pharmacopoeial and Regulatory Status

Lythri herba's quality is specified in the European Pharmacopoeia; however, purple loosestrife has not yet been evaluated by the EMA's Herbal Medicines Committee (HMPC) or ESCOP. Purple loosestrife has not yet been classified as a traditional medicinal product under the EU Traditional Herbal Medicinal Products Directive. Consequently, no formal risk/benefit assessment at the level of a regulatory submission has been completed.

8.2 Genotoxicity Concerns

A notable safety signal has emerged regarding the genotoxic potential of the plant's tannin content. Tannins have been demonstrated to have genotoxic capacity. A study assessing the genotoxic potential of Lythrum salicaria L. extract by the mussel micronucleus test (using Unio pictorum) found that the extract had a high hydrolysable tannin content and significant mutagenic effect. The authors concluded that as L. salicaria has been long used in traditional medicine for chronic diarrhoea, dysentery, leucorrhoea, and blood-spitting, its genotoxic potential should be evaluated not only with regard to potential effects in the aquatic ecosystem but also with respect to its safe use as a medicinal herb.

8.3 Cytotoxicity at High Concentrations

On the Artemia salina L. biotester, although the extract is non-toxic, cytological effects appear after 48 hours (including accumulation of cytoplasmic inclusions, an increase of intercellular space, and cell detachments). Extracts showed low cytotoxicity on studied normal and cancer cell lines at the concentrations tested in in vitro systems.

8.4 Tannin-Related Drug Interactions

Because Lythri herba is a high-tannin plant material, the interaction risks generally associated with tannin-rich botanicals are relevant. Tannins are known to bind to and precipitate proteins, and can complex with alkaloids, metal ions, and other drugs when co-administered, potentially reducing the bioavailability of orally administered iron salts, basic drugs, and certain antibiotics. No specific drug interaction studies on Lythrum salicaria preparations in humans have been published.

8.5 Adulteration of Commercial Preparations

In most commercial samples of purple loosestrife herb analyzed in the 2015 review, undeclared components have been detected, such as bindweed (Convolvulus) and ragweed (Ambrosia), which are known to have toxic potential. This represents a material quality and safety concern for any preparation sold outside of pharmacopoeially controlled supply chains.

8.6 Invasive Species Regulatory Context

L. salicaria is considered one of the 100 worst invasive alien species in the world by the IUCN. In several North American jurisdictions, cultivation, sale, or transport of the live plant is regulated or prohibited. The harvesting of wild plant material for medicinal use may be subject to regional environmental regulations.

8.7 Data Gaps

No formal clinical safety trials, reproductive toxicity studies, or formal pharmacokinetic studies in humans have been published for Lythrum salicaria preparations. The absence of EMA HMPC evaluation means no official safety assessment — including pregnancy and lactation guidance — is available from a regulatory body.

References

• Piwowarski JP et al. (2015). Lythrum salicaria L.—Underestimated medicinal plant from European traditional medicine. A review. Journal of Ethnopharmacology. ScienceDirect.
• Piwowarski JP et al. (2021). Lythrum salicaria Ellagitannins Stimulate IPEC-J2 Cells Monolayer Formation and Inhibit Enteropathogenic Escherichia coli Growth and Adhesion. Journal of Natural Products. PMC7771025.
• Aziz MA et al. (2013). Biological activity and microscopic characterization of Lythrum salicaria L. PMC3751246.
• Srecković N et al. (2025). Therapeutic Potential of Lythrum salicaria L. Ethanol Extract in Experimental Rat Models of Streptozotocin-Induced Diabetes Mellitus and Letrozole-Induced Polycystic Ovary Syndrome. PMC12108253.
• Virchea LI et al. (2025). Assessment of Purple Loosestrife (Lythrum salicaria L.) Extracts from Wild Flora of Transylvania: Phenolic Profile, Antioxidant Activity, In Vivo Toxicity, and Gene Expression Variegation Studies. Pharmaceutics. DOI: 10.3390/pharmaceutics17091097.
• Danci O et al. (2025). Optimized Sambucus nigra L., Epilobium hirsutum L., and Lythrum salicaria L. Extracts: Biological Effects Supporting Their Potential in Wound Care. PMC12108421.
• Piwowarski JP et al. (2020). Lythrum salicaria L. herb and gut microbiota of healthy post-weaning piglets. Focus on prebiotic properties and formation of postbiotic metabolites in ex vivo cultures. PubMed PMID 32673710.
• Turker AU et al. (2016). Burn wound healing activity of Lythrum salicaria L. and Hypericum scabrum L. PubMed PMID 27701123.
• Tunalier Z et al. (2007). Antioxidant, anti-inflammatory, anti-nociceptive activities and composition of Lythrum salicaria L. extracts. PubMed PMID 17125946.
• Srecković N et al. (2020). Lythrum salicaria L. (Lythraceae) as a promising source of phenolic compounds in the modulation of oxidative stress: Comparison between aerial parts and root extracts. Industrial Crops and Products. ScienceDirect.
• Srećković N et al. (2026). Bioactive Phytocompound Profiling and the Evaluation of Antioxidant, Antihyperglycemic, and Antimicrobial Activities of Medicinal Plants from Serbian Traditional Medicine. Molecules. DOI: 10.3390/molecules31010197.
• Humadi SS, Istudor V (2009). Lythrum salicaria (Purple loosestrife). Medicinal use, extraction and identification of its total phenolic compounds. Farmacia, Vol. 57(2):192–199.
• Al-Snafi AE (2019). Chemical constituents and pharmacological effects of Lythrum salicaria — A review. IOSR Journal of Pharmacy, 9(6):51–59.
• Piwowarski JP, Kiss AK (2013). C-glucosidic Ellagitannins from Lythri herba (European Pharmacopoeia): Chromatographic Profile and Structure Determination. ResearchGate.
• Farkas A et al. (2015). Genotoxic Effect of Lythrum salicaria Extract Determined by the Mussel Micronucleus Test. Biologia Futura. Springer.
• Arzneipflanzenlexikon (Herbal Drug Lexicon). Purple loosestrife — medicinal use of the drug: indications, dosage, side effects, interactions, and warnings.
• ScienceDirect Topics. Lythrum salicaria — an overview (referencing Piwowarski et al. 2015 review).